Key result
Left atrial appendage occlusion serves as a valid alternative to anticoagulation for stroke prevention in patients with atrial fibrillation who cannot tolerate anticoagulant therapy.
Why the study?
Multiple LAAO devices have been developed and tested over the last decade for patients with AF who do not tolerate anticoagulation, warranting an overview of the current state of the art.
This review summarizes the current evidence and commercially available devices for left atrial appendage occlusion in patients with atrial fibrillation who cannot tolerate anticoagulation.
Atrial fibrillation is the most common cardiac arrhythmia and is associated with morbidity and mortality due to cerebral or systemic embolization, with cardiac thrombi mainly forming in the left atrial appendage (LAA). Anticoagulation is the treatment of choice; however, in patients who do not tolerate anticoagulation, LAA occlusion (LAAO) is a valid alternative. Over the last decade, many different LAAO devices have been developed and tested in trials, providing good clinical results. The purpose of this paper is to make an overview of the current state of the art of LAAO procedure, with a focus on available devices and future perspectives.
No takes yet. Share an insight, caveat, or question.
Maurina et al. (2021) conducted a review in Atrial fibrillation. Left atrial appendage occlusion (LAAO) vs. Anticoagulation (implied) was evaluated. Left atrial appendage occlusion serves as a valid alternative to anticoagulation for stroke prevention in patients with atrial fibrillation who cannot tolerate anticoagulant therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: